Primary Systemic Vasculitis

Evidence-Based Rheumatology

Volumn , Issue , 2009, Pages 495-527

  Watts, Richard A ^a   Lane, Suzanne E ^b   Scott, David Gl ^c  

^a IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Antineutrophil cytoplasmic antibodies (ANCA); CYCAZAREM trial; Low predictive values predicting relapse; Maintenance therapy azathioprine and methotrexate (MTX); Pneumocystis carinii pneumonia (PCP); Primary systemic vasculitis; Pulse versus oral cyclophosphamide in primary systemic vasculitis; Vasculitis and azathioprine; Vasculitis decision aid; Wegener's granulomatosis (WG) and Churg Strauss syndrome (CSS)

Indexed keywords

EID: 14044270464     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444315844.ch13     Document Type: Chapter

References (44)

1. Watts R, Lane S, Bentham G, Scott D. Epidemiology of systemic vasculitis-a 10 year study in the United Kingdom. Arthritis Rheum 2000; 43: 422-7.
2. Walton EW. Giant cell granuloma of the respiratory tract. Br Med J 1958; 2: 265-70.
3. Fauci A, Wolff S. Wegener's granulomatosis: studies in 18 patients and a review of the literature. Medicine 1973; 52: 535-61.
4. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
5. Gordon C, Luqmani R, Adu D. Relapses in patients with a systemic vasculitis. Q J Med 1993; 86: 779-89.
6. Wiik A. The rational use of ANCA in the diagnosis in the diagnosis of vasculitis. Rheumatology 2002; 41: 481-3.
7. Bacon PA, Luqmani. Assessment of Disease, Activity and Damage. In: Ball GV, Bridges SL, eds. Vasculitis. Oxford: Oxford University of Press, 2002: 246-54.
8. Frohnert PP, Sheps SG. Long term follow-up of periarteritis nodosa. Am J Med 1967; 43: 8-14.
9. Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967; 67: 393-8.
10. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
11. Guillevin L, Jarrousse B, Lok C, et al. Long term follow-up after treatment of polyarteritis nodosa and Churg Strauss angiitis with comparison of steroids, plasma exchanges and cyclophosphamide to steroids and plasma exchange. A prospective randomised trial of 71 patients. J Rheumatol 1991; 18: 567-74.
12. Gayraud M, Guillevin L, Toumelin PL, et al. Long-term follow up of polyarteritis nodosa, microscopic polyangiitis, and Churg Strauss syndrome: analysis of 4 prospective trials including 278 patients. Arthritis Rheum 2001; 44: 668-77.
13. Rasmussen N, Abramowicz D, Andrassy K, et al. European therapeutic trials in ANCA-associated vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995; 101(Suppl 1): 29-34.
14. De Groot K, Adu D, Savage COS. The value of pulse cyclophosphamide in ANCA-associated vasculitis: metaanalysis and critical review. Nephrol Dialysis Transplant 2001; 16: 2018-27.
15. Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36: 1290-7.
16. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomised trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalised Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-98.
17. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J Med 1997; 90: 401-9.
18. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomised study. Arthritis Rheum 1998; 41: 1835-44.
19. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001; 13: 48-55.
20. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13.
21. De Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998; 25: 492-5.
22. Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26: 1134-9.
23. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43: 1836-40.
24. DeGroot K, Rasmussen N, Cohen-Tervaert JW, Jayne DRW for EUVAS. Randomised trial of cyclophosphamide versus methotrexate for induction of remission in nonrenal ANCA-associated vasculitis. Clev Clin J Med 2002; 69 (Suppl l2): 116 (abstract).
25. Jayne D, Rasmussen N, Andrassy K, for the European Vasculitis Study Group. A randomised trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
26. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666-73.
27. de Groot K, Reinhold-Keller E, Tatsis E, et al. Therapy for maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39: 2052-61.
28. Cohen-Tervaert JW, Huitma MG, Hene RJ, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-11.
29. Cohen-Tervaert JW, Stegeman CA, Kallenberg CGM. Serial ANCA testing is useful in monitoring disease activity in patients with ANCA associated vasculitides. Sarcoidosis Vasc Dif Lung Dis 1996; 13: 246-8.
30. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibodies. A prospective study. Arthritis Rheum 2000; 43: 2025-33.
31. Girard T, Mahr A, Noel LH et al. Are anti-neutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001; 40: 147-51.
32. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Resp Crit Care Med 1995; 151: 795-9.
33. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32.
34. Godeau B, Mainardi JL, Roudot-Thoraval F et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis 1995; 54: 991-4.
35. Chung JB, Armstrong K, Schwartz JS, Albert D. Costeffectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 2000; 43: 1841-8.
36. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124: 477-84.
37. Stilwell TJ, Benson RC, DeRemee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988; 31: 465-70.
38. Guillevin L, Fain O, Lhote F, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomised trial in 78 patients. Arthritis Rheum 1992; 35: 208-15.
39. Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomised trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638-45.
40. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757-63.
41. Luqmani RA, Jayne D, Gaskin G on behalf of EUVAS. Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCAassociated glomerulonephritis. Arthritis Rheum 2002 Suppl. S207 (abstract).
42. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000; 93(7): 433-9.
43. Jayne D, Esnault V, Lockwood C. ANCA anti-idiotypic antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmunity 1993; 6: 207-19.
44. Richter C, Schnabel A, Csernok E, et al. Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high dose intravenous immunoglobulin. Clin Exp Immunol 1995; 101: 2-7.